Primary CNS lymphoma
- 1 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Neurology
- Vol. 3 (1), 24-35
- https://doi.org/10.1038/ncpneuro0395
Abstract
Non-Hodgkin's lymphoma invades the brain, the vitreous body and nerves of the eye, the meninges, and the nerve roots of brain and spine, leading to the development of a primary CNS lymphoma. The mechanism of involvement of these locations by malignant B lymphocytes is unknown, but it might involve molecular targeting of lymphoma cells generated at cryptic systemic sites. The diagnosis of primary CNS lymphoma has been facilitated by advances in imaging techniques and the discovery of molecular markers. Methotrexate-based regimens, even when radiation is deferred, prolong overall survival to over 5 years, but relapses eventually occur in most cases. Better tools for earlier diagnosis and monitoring of treatment response will emerge from molecular studies of therapeutic targets.Keywords
This publication has 72 references indexed in Scilit:
- Highly Active Antiretroviral Therapy and Human Immunodeficiency Virus–Associated Primary Cerebral LymphomaJNCI Journal of the National Cancer Institute, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Primary Central Nervous System Posttransplant Lymphoproliferative DisordersAmerican Journal of Clinical Pathology, 2004
- The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphomaCancer, 2002
- Gammaherpesviruses and “Hit-and-Run” OncogenesisThe American Journal of Pathology, 2000
- Primary Central Nervous System Lymphomas Are Derived from Germinal-Center B Cells and Show a Preferential Usage of the V4–34 Gene SegmentThe American Journal of Pathology, 1999
- Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapyNeurology, 1996
- Combined‐modality therapy in the treatment of primary central nervous system lymphoma in AIDSNeurology, 1994
- Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 8315International Journal of Radiation Oncology*Biology*Physics, 1992
- The Immunodeficiency Cancer RegistryJournal of Pediatric Hematology/Oncology, 1987